- Home
- REPL vs CRMD Comparison
REPL vs CRMD Comparison
Compare REPL & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- CRMD
- Stock Information
- Founded
- REPL 2015
- CRMD 2006
- Country
- REPL United States
- CRMD United States
- Employees
- REPL N/A
- CRMD N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- CRMD Health Care
- Exchange
- REPL Nasdaq
- CRMD Nasdaq
- Market Cap
- REPL 578.4M
- CRMD 464.7M
- IPO Year
- REPL 2018
- CRMD 2010
- Fundamental
- Price
- REPL $8.98
- CRMD $12.14
- Analyst Decision
- REPL Strong Buy
- CRMD Strong Buy
- Analyst Count
- REPL 6
- CRMD 6
- Target Price
- REPL $20.00
- CRMD $15.00
- AVG Volume (30 Days)
- REPL 1.6M
- CRMD 2.2M
- Earning Date
- REPL 05-22-2025
- CRMD 05-06-2025
- Dividend Yield
- REPL N/A
- CRMD N/A
- EPS Growth
- REPL N/A
- CRMD N/A
- EPS
- REPL N/A
- CRMD 0.28
- Revenue
- REPL N/A
- CRMD $82,553,827.00
- Revenue This Year
- REPL N/A
- CRMD $239.16
- Revenue Next Year
- REPL N/A
- CRMD $53.17
- P/E Ratio
- REPL N/A
- CRMD $43.73
- Revenue Growth
- REPL N/A
- CRMD N/A
- 52 Week Low
- REPL $4.93
- CRMD $3.61
- 52 Week High
- REPL $17.00
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- REPL 53.81
- CRMD 63.16
- Support Level
- REPL $8.25
- CRMD $11.39
- Resistance Level
- REPL $9.53
- CRMD $12.99
- Average True Range (ATR)
- REPL 0.88
- CRMD 0.49
- MACD
- REPL 0.17
- CRMD -0.10
- Stochastic Oscillator
- REPL 71.10
- CRMD 52.25
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.